Cerebral Palsy
Recent clinical, regulatory, research and industry developments relating to this disease.
Inflammatory mediators drive neuroinflammation in autism spectrum disorder and cerebral palsy.
Neurologic and developmental disability at six years of age after extremely preterm birth.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 4 clinical trials expected to report results, the earliest in Q2 2028.
- Q2 2028Assessment of the Role of Antenatal Magnesium Sulphate in High-Risk Preterm Patients With Cerebral Palsy: a Randomized Clinical Trial
- Q1 2029Advancing Neurorehabilitation: Evaluating Transcutaneous Spinal Stimulation and 5-Azacitidine for Enhanced Motor Outcomes in Cerebral Palsy
- Q4 2029Pharmacogenomic Contribution to the Biotransformation of Trihexyphenidyl and Development of a Precision Dosing Model for Children With Dystonia and Cerebral Palsy
- Q3 2030Smart Ankle-Foot Orthosis and 5-Azacitidine to Enhance Gait and Community Mobility for Children With Cerebral Palsy
Clinical MilestonesViewHide
- 2026-06-24Pharmacogenomic Contribution to the Biotransformation of Trihexyphenidyl and Development of a Precision Dosing Model for Children With Dystonia and Cerebral PalsyResults expected Q4 2029
- 2026-06-01Smart Ankle-Foot Orthosis and 5-Azacitidine to Enhance Gait and Community Mobility for Children With Cerebral PalsyResults expected Q3 2030
- 2026-05-29Advancing Neurorehabilitation: Evaluating Transcutaneous Spinal Stimulation and 5-Azacitidine for Enhanced Motor Outcomes in Cerebral PalsyResults expected Q1 2029
- 2026-04-13Assessment of the Role of Antenatal Magnesium Sulphate in High-Risk Preterm Patients With Cerebral Palsy: a Randomized Clinical TrialResults expected Q2 2028
- 2026-07-01Allogeneic Umbilical Cord Mesenchymal Stem Cells and Conditioned Medium for Cerebral Palsy in ChildrenPrimary completion
- 2026-03-31A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral PalsyCompleted
- 2026-07-01ClinicalAllogeneic Umbilical Cord Mesenchymal Stem Cells and Conditioned Medium for Cerebral Palsy in ChildrenPrimary completion
- 2026-06-24ClinicalPharmacogenomic Contribution to the Biotransformation of Trihexyphenidyl and Development of a Precision Dosing Model for Children With Dystonia and Cerebral PalsyResults expected Q4 2029
- 2026-06-01ClinicalSmart Ankle-Foot Orthosis and 5-Azacitidine to Enhance Gait and Community Mobility for Children With Cerebral PalsyResults expected Q3 2030
- 2026-05-29ClinicalAdvancing Neurorehabilitation: Evaluating Transcutaneous Spinal Stimulation and 5-Azacitidine for Enhanced Motor Outcomes in Cerebral PalsyResults expected Q1 2029
- 2026-04-13ClinicalAssessment of the Role of Antenatal Magnesium Sulphate in High-Risk Preterm Patients With Cerebral Palsy: a Randomized Clinical TrialResults expected Q2 2028
- 2026-03-31ClinicalA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral PalsyCompleted
- 2025-09-22ClinicalEvaluation of the Long-term Efficacy of the Injection of Botulinum Toxin A Into the Salivary Glands Versus Scopolamine Patches in the Treatment of Drooling in Children Over 4 Years Old With Cerebral Palsy.Terminated
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes4
- Cerebral Palsy2
- Autism Spectrum Disorder1
- Children with Disabilities1
- Infant, Premature1
Leading journals3
- Scientific reports1
- Seminars in fetal & neonatal medicine1
- The New England journal of medicine1
Leading researchers8
- Badawi N1
- Bracewell MA1
- Dang VD1
- Gecz J1
- Hoang DH1
- Marlow N1
- Nguyen LT1
- Nguyen PAT1
Affiliations (unnormalised)6
- Adelaide Medical School1
- Children's Hospital Westmead Clinical School1
- College of Health Sciences1
- Leibniz Institute1
- School of Human Development1
- Vinmec Hi-Tech Center and Vinmec-VinUni Institute of Immunology1
Reference
Authoritative identity, definition & identifiers.
A heterogeneous group of nonprogressive motor disorders caused by chronic brain injuries that originate in the prenatal period, perinatal period, or first few years of life. The four major subtypes are spastic, athetoid, ataxic, and mixed cerebral palsy, with spastic forms being the most common. The motor disorder may range from difficulties with fine motor control to severe spasticity (see MUSCLE SPASTICITY) in all limbs. Spastic diplegia (Little disease) is the most common subtype, and is characterized by spasticity that is more prominent in the legs than in the arms. Pathologically, this condition may be associated with LEUKOMALACIA, PERIVENTRICULAR. (From Dev Med Child Neurol 1998 Aug;40(8):520-7)
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.